Journal Updates
eMediNexus Coverage from: 
Shorter Combo Treatment OK in Stage III CRC
eMediNexus,  20 May 2019
remove_red_eye 462 Views
#Gastroenterology #Hematology #Oncology #Pharmacist #Radiology

0 Read Comments                

While a shorter duration of adjuvant chemotherapy does not appear to increase the risk of death in stage III colon cancer patients on combination regimens, those receiving monotherapy should have the entire 6 months of treatment, suggested the authors of a new meta-analysis published in JAMA Network Open.The meta-analysis of 22 studies involving 43,671 patients with stages II or III disease included two randomized trials and 20 observational studies. The auth
To continue reading this article
Sign in with Medtalks

Continue reading your article with a eMediNexus account.
Free Membership!